Credit: Canadian Light Source The researchers found that when the Ras protein is in its mutated, cancer-causing state, "molecules snuggle inside the pocket. Using crystallography, we were able to ...

Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a ...

Because the KRAS protein is difficult to block, Dr. Grisham, Dr. Solit, and their colleagues believe this combination approach is likely to be more effective. Ellen was first diagnosed with stage 3 ...

Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected ...

KRAS G12C is one of several genetic mutations known to activate the KRAS protein, which drives tumor growth and progression. KRAS mutations are present in up to 45% of colorectal cancer cases, but ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope ...

KRAS G12C is one of several genetic mutations that are known to activate the KRAS protein, which drives tumor growth and progression. KRAS mutations are present in up to 45% of colorectal cancer ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy ...